A comparative study on the pharmacokinetics of methotrexate in a dose range of 0.5 g to 33.6 g/m2 in children with acute lymphoblastic leukemia.
about
Optimizing antimetabolite-based chemotherapy for the treatment of childhood acute lymphoblastic leukaemia.Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections.Intravitreal chemotherapy for the treatment of recurrent intraocular lymphoma.High-dose methotrexate in acute lymphoblastic leukemia: where is the evidence for its continued use?Evidence for CSF accumulation of 5-methyltetrahydrofolate during repeated courses of methotrexate plus folinic acid rescue.Plasma methotrexate, red blood cell methotrexate, and red blood cell folate values and outcome in children with precursor B-acute lymphoblastic leukemia: a report from the Children's Oncology Group.Treatment approaches for primary CNS lymphomas.Chemotherapy in newly diagnosed primary central nervous system lymphoma.Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma.Pharmacokinetics and metabolism of methotrexate: an example for the use of clinical pharmacology in pediatric oncology.Diagnosis and treatment of primary CNS lymphoma.Pharmacokinetics of high-dose methotrexate in infants aged less than 12 months treated for aggressive brain tumors.Methotrexate pharmacology and resistance in childhood acute lymphoblastic leukemia.Critical factors for the reversal of methotrexate cytotoxicity by folinic acid.The degree of myelosuppression during maintenance therapy of adolescents with B-lineage intermediate risk acute lymphoblastic leukemia predicts risk of relapse.Pharmacodynamics of high-dose methotrexate in pediatric patients.Cerebrospinal fluid and plasma methotrexate levels following high-dose regimen given as a 3-hour intravenous infusion in children with nonHodgkin's lymphoma.High dose methotrexate treatment in children with acute lymphoblastic leukaemia may be optimised by a weight-based dose calculation.Cerebrospinal fluid drug levels of leukemic children receiving intravenous 5 g/m2 methotrexate.Genetic polymorphisms predicting methotrexate blood levels and toxicity in adult non-Hodgkin lymphoma.Primary CNS Lymphoma.
P2860
Q33994352-BDA8B850-3C10-403A-9039-CAF32C345C6FQ34807224-C302F3CE-65F8-48D3-AFED-86D4E1BC658DQ35309325-1FB0DD5E-A970-4E73-BA3A-AFA64EDD55A5Q36130633-700E3DB0-0C94-44ED-8B6A-9CA8FCF7C2CFQ36467591-9D0C9D2C-6ED9-4F29-8774-0AFA4ED3CEDCQ37166872-FD8F5D70-7E5C-4DF1-BB60-A4DF8C3CFD30Q37739428-1928E8B6-F73A-466E-AFF2-B05D7145DC29Q37905596-4F9F3E51-9EA6-4782-835A-4EE45BC5ECC5Q37911948-EE5C3069-BEFF-440C-BC95-207B72161386Q37951561-310FE33E-C9B9-457C-A7B3-28BDAF942202Q38106613-C9E75A19-8CEE-4C96-83F3-437C94225984Q39911676-89BD3243-91B6-4FDF-BDFD-D8546C522CE4Q41489289-BA399AAA-394D-4448-AA44-C6A1A57ECC42Q41696472-350AAE2E-4214-45CE-A45F-235B3CFCCDD0Q43174427-B48F427F-B831-4749-852C-1B0421A5306AQ44114511-5D9673A0-1E6C-494D-9455-83B7EE5FDE65Q45030593-FB2D6429-74E0-48F3-85A2-5BCD2BF77BB4Q47385414-E2653AD5-633E-4897-AF82-0C90792C2EB7Q48117441-31570BB7-98E6-4B1B-90D6-13E529C15431Q50856551-09E7003A-9478-4EE7-971B-EBCAB31305B3Q51841565-5C453B7B-007C-4A3A-9DCE-5F8A90ED49FF
P2860
A comparative study on the pharmacokinetics of methotrexate in a dose range of 0.5 g to 33.6 g/m2 in children with acute lymphoblastic leukemia.
description
1987 nî lūn-bûn
@nan
1987年の論文
@ja
1987年学术文章
@wuu
1987年学术文章
@zh
1987年学术文章
@zh-cn
1987年学术文章
@zh-hans
1987年学术文章
@zh-my
1987年学术文章
@zh-sg
1987年學術文章
@yue
1987年學術文章
@zh-hant
name
A comparative study on the pha ...... acute lymphoblastic leukemia.
@en
A comparative study on the pha ...... acute lymphoblastic leukemia.
@nl
type
label
A comparative study on the pha ...... acute lymphoblastic leukemia.
@en
A comparative study on the pha ...... acute lymphoblastic leukemia.
@nl
prefLabel
A comparative study on the pha ...... acute lymphoblastic leukemia.
@en
A comparative study on the pha ...... acute lymphoblastic leukemia.
@nl
P1433
P1476
A comparative study on the pha ...... acute lymphoblastic leukemia.
@en
P356
10.1002/1097-0142(19870701)60:1<5::AID-CNCR2820600103>3.0.CO;2-D
P407
P577
1987-07-01T00:00:00Z